1stOncology™: Cancer Intelligence Service – Page 13163 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Crescendo Biologics to collaborate with world-leading oncology groups at the University of Oxford and the University of Surrey

On September 12, 2019 Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T cell enhancing therapeutics, reported that it has signed collaborations with worldrenowned oncology research groups at the University of Oxford and the University of Surrey (Press release, Crescendo Biologics, SEP 12, 2019, View Source [SID1234539465]). These collaborations will accelerate the development of CB307, Crescendo’s lead programme for PSMA positive tumours, and its follow-on pipeline of CD137-directed T cell enhancing programmes.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The Department of Oncology at the University of Oxford is one of the world’s leading cancer research centres. Dr Kerry Fisher’s group within this department, focuses on deepening our understanding of the tumour microenvironment to develop innovative new therapies for cancer patients.

Professor Hardev Pandha is a clinician scientist and a medical oncologist at the University of Surrey. He is head of the University’s Targeted Cancer Therapy research group, Director of the Surrey Cancer Research Institute and an expert in the management of patients with urological cancers. Professor Pandha leads a highly respected team with key interests in early phase clinical trials with targeted agents and novel therapies in translational settings.

Theodora Harold, CEO of Crescendo Biologics, commented:

Professor Pandha and Dr Fisher each head up world-leading groups-it is a credit to the quality of our science to be able to collaborate with them. Their multidisciplinary and collaborative approaches to oncology research will allow Crescendo to gain a greater understanding of these difficult to treat cancers and support us to deliver first in class, targeted T cell therapies."

Dr Kerry Fisher, Department of Oncology, University of Oxford, commented: "We look forward to working with Crescendo to further explore and understand the mechanisms driving the development of cancers and applying our group’s translational expertise to advance Crescendo’s novel Humabody programmes."

Professor Hardev Pandha, University of Surrey, added:

"We are delighted to be exploring the potential of Crescendo’s novel, targeted, T cell co-stimulatory molecules to deliver therapeutic benefit to patients with high unmet medical need."

Bristol-Myers Squibb to Announce Results for Third Quarter 2019 on October 31, 2019

On September 12, 2019 Bristol-Myers Squibb Company (NYSE:BMY) reported that it will announce results for the third quarter of 2019 on Thursday, October 31, 2019 (Press release, Bristol-Myers Squibb, SEP 12, 2019, View Source [SID1234539464]). During a conference call at 8:30 a.m. ET on October 31, company executives will review financial information and will address inquiries from investors and analysts.

Investors and the general public are invited to listen to a live webcast of the call at View Source or by dialing in the U.S. toll free 800-458-4212 or international 786-789-4772, confirmation code: 532230. Materials related to the call will be available at the same website prior to the conference call. A replay of the call will be available beginning at 11:45 a.m. ET on October 31 through 11:45 a.m. ET on November 4, 2019. The replay will also be available through View Source or by dialing in the U.S. toll free 888-203-1112 or international 719-457-0820, confirmation code: 532230.

VAXIMM Announces Presentations at Upcoming Industry and Scientific Events

On September 12, 2019 VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, reported that the Company will participate in several events around the globe in the coming months (Press release, Vaximm, SEP 12, 2019, View Source [SID1234539461]). Company representatives will be available for networking and one-on-one meetings at the following conferences:

3rd Annual China Cross-Border Healthcare Investment Summit
September 17-20, 2019
Hangzhou & Chengdu, China

Dr. Heinz Lubenau, Chief Operating Officer & Co-Founder of VAXIMM, will give corporate presentations and participate in one-on-one meetings with top-tier Chinese healthcare investors. The program can be found here.

5th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (CIMT) (Free CIMT Whitepaper)
September 25-28, 2019
Paris, France

VAXIMM representatives will be available for one-on-one meetings during the conference. To schedule a meeting, please contact [email protected].

25th Annual International Partnering Conference BIO-Europe
November 11-13, 2019
Hamburg, Germany

VAXIMM plans to give a corporate presentation and host one-on-one meetings at this event. To request a meeting, please sign up through the event’s partneringONE meeting system.

Jefferies 2019 London Healthcare Conference
November 20-21, 2019
London, UK

Management will be available for one-on-one meetings.

4th Annual NeoAg Summit
November 20-22, 2019
Boston, USA

Dr. Lubenau will give a presentation entitled, "Oral T-Cell Therapies for Personalized Neoantigen-Targeting Treatment," during the session, "Clinical & Translational – Interrogating the Best Manufacturing Platforms to Reduce Needle to Needle Time," on November 22 at 11 AM ET. The program can be found here.

Daiichi Sankyo Announces Launch of Oxycodone Extended Release Tablets NX “Daiichi Sankyo” for Sustained Cancer Pain Treatment in Japan

On September 12, 2019 Daiichi Sankyo Company Limited (hereafter, Daiichi Sankyo) reported it has launched a new generic formulation of oxycodone hydrochloride hydrate extended release tablets for sustained cancer pain treatment in Japan: Oxycodone Extended Release Tablets 5 mg, 10 mg, 20 mg and 40 mg NX "Daiichi Sankyo" (hereafter, new formulation) (Press release, Daiichi Sankyo, SEP 12, 2019, View Source [SID1234539458]).

The new formulation of oxycodone hydrochloride, a strong opioid analgesic providing relief of moderate to severe pain in various types of cancer, contains the narcotic antagonist naloxone in order to prevent abuse.

It is manufactured from drug substance to formulation solely by Daiichi Sankyo’s subsidiary in Japan, Daiichi Sankyo Propharma Co., Ltd. (marketing authorization holder).

The addition of the new formulation to our product lineup of opioid analgesics will provide another treatment option to patients suffering from cancer pain and further enhance our contribution to healthcare in Japan.

Product Name

Therapeutic

Isofol Announces that an Abstract has been Accepted for Presentation at the 2019 ESMO Congress

On September 12, 2019 Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), reported that an abstract highlighting the study design of its ongoing pivotal/registration-based AGENT clinical study (ISO-CC-007) in metastatic colorectal cancer (mCRC) will be presented at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) 2019 Congress, to be held from September 27 to October 1, 2019, in Barcelona, Spain (Press release, Isofol Medical, SEP 12, 2019, View Source [SID1234539446]).

Dr. Roger Tell, chief medical officer of Isofol, said, "The abstract will be presented as a poster and will highlight the design and execution to date of the AGENT study. The study evaluating the effectiveness of arfolitixorin, in combination with other drugs, compared to current standard treatment for patients affected by mCRC. The AGENT study is important, as very few new drugs have been introduced to the mCRC treatment landscape in the last decade, including no new early-line therapies. With the preliminary hopeful results we have achieved with arfolitixorin in our ongoing Phase 1/2 study (ISO-CC-005), we are pleased to present our clinical development program with arfolitixorin at the this year´s ESMO (Free ESMO Whitepaper) congress."

The AGENT study is a multicentre, randomized, parallel-group Phase 3 clinical study evaluating arfolitixorin as a new experimental therapy for the treatment of mCRC in first-line treatment. The study is recruiting patients at approximately 70 global sites. Dr. Josep Tabernero, head of the Medical Oncology Department at the Vall d’Hebron Barcelona Hospital Campus, and Director of the Vall d’Hebron Institute of Oncology, is the study’s coordinating investigator and Dr. Heinz-Josef Lenz, Co-Leader, Gastrointestinal Cancers Program, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, US, is the principal investigator in North America.

ESMO is the largest oncology conference in Europe and will be attended by approximately 25,000 clinicians, researchers and representatives of the pharmaceutical and biotechnology sector.

The poster will be published on-line via the ESMO (Free ESMO Whitepaper) website on September 23, 2019 and will presented on-site on September 29, 2019 at the poster area, Hall 4.

For further information, please contact

Isofol Medical AB (publ)

Roger Tell, SVP, Chief Medical Officer
Email: [email protected]
Phone: +46 (0)760 293 911

Investor Relations

LifeSci Advisors
Hans Herklots
E-mail: [email protected]
Phone: +41 79 598 7149

Media
LifeSci Public Relations
Alison Chen
E-mail: [email protected]
Phone: +1 646 876 4932

Certified Adviser
FNCA Sweden AB
E-mail: [email protected]
Phone: +46 (0)8 528 003 99

About arfolitixorin

Arfolitixorin is Isofol’s proprietary drug candidate being developed to increase the efficacy of standard of care chemotherapy for advanced colorectal cancer. The drug candidate is currently being studied in a global Phase 3 clinical trial, AGENT. As the key active metabolite of the widely used folate-based drugs, arfolitixorin can potentially benefit all patients with advanced colorectal cancer, as it does not require complicated metabolic activation to become effective.